30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

October 9, 2014 updated by: Boehringer Ingelheim

A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise

The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30 mg, or 45 mg, administered orally once daily), and linagliptin (5 mg, administered orally once daily). In addition, durability of treatment effect and safety under chronic treatment conditions will be investigated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

936

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Estonia
      • Harju, Estonia
        • 1264.3.37207 Boehringer Ingelheim Investigational Site
      • Pärnu, Estonia
        • 1264.3.37209 Boehringer Ingelheim Investigational Site
      • Tallin, Estonia
        • 1264.3.37203 Boehringer Ingelheim Investigational Site
      • Tallin, Estonia
        • 1264.3.37204 Boehringer Ingelheim Investigational Site
      • Tallin, Estonia
        • 1264.3.37205 Boehringer Ingelheim Investigational Site
      • Tallinn, Estonia
        • 1264.3.37201 Boehringer Ingelheim Investigational Site
      • Tallinn, Estonia
        • 1264.3.37202 Boehringer Ingelheim Investigational Site
      • Tallinn, Estonia
        • 1264.3.37208 Boehringer Ingelheim Investigational Site
      • Tartu, Estonia
        • 1264.3.37206 Boehringer Ingelheim Investigational Site
      • Viljandi County, Estonia
        • 1264.3.37210 Boehringer Ingelheim Investigational Site
  • Germany
      • Bad Lauterberg / Harz, Germany
        • 1264.3.49001 Boehringer Ingelheim Investigational Site
      • Dietzenbach, Germany
        • 1264.3.49007 Boehringer Ingelheim Investigational Site
      • Dortmund, Germany
        • 1264.3.49002 Boehringer Ingelheim Investigational Site
      • Essen, Germany
        • 1264.3.49009 Boehringer Ingelheim Investigational Site
      • Hamburg, Germany
        • 1264.3.49003 Boehringer Ingelheim Investigational Site
      • Ingelheim, Germany
        • 1264.3.49012 Boehringer Ingelheim Investigational Site
      • Leipzig, Germany
        • 1264.3.49008 Boehringer Ingelheim Investigational Site
      • Mainz, Germany
        • 1264.3.49005 Boehringer Ingelheim Investigational Site
      • Offenbach, Germany
        • 1264.3.49010 Boehringer Ingelheim Investigational Site
      • Stuhr, Germany
        • 1264.3.49004 Boehringer Ingelheim Investigational Site
  • Latvia
      • Daugavpils, Latvia
        • 1264.3.37105 Boehringer Ingelheim Investigational Site
      • Daugavpils, Latvia
        • 1264.3.37112 Boehringer Ingelheim Investigational Site
      • Daugavpils, Latvia
        • 1264.3.37113 Boehringer Ingelheim Investigational Site
      • Jelgava, Latvia
        • 1264.3.37110 Boehringer Ingelheim Investigational Site
      • Liepaja, Latvia
        • 1264.3.37101 Boehringer Ingelheim Investigational Site
      • Ogre, Latvia
        • 1264.3.37106 Boehringer Ingelheim Investigational Site
      • Riga, Latvia
        • 1264.3.37104 Boehringer Ingelheim Investigational Site
      • Riga, Latvia
        • 1264.3.37108 Boehringer Ingelheim Investigational Site
      • Riga, Latvia
        • 1264.3.37109 Boehringer Ingelheim Investigational Site
      • Riga, Latvia
        • 1264.3.37111 Boehringer Ingelheim Investigational Site
      • Talsi, Latvia
        • 1264.3.37107 Boehringer Ingelheim Investigational Site
      • Tukums, Latvia
        • 1264.3.37102 Boehringer Ingelheim Investigational Site
      • Valmiera, Latvia
        • 1264.3.37103 Boehringer Ingelheim Investigational Site
  • Spain
      • Badía del Vallès - Barcelona, Spain
        • 1264.3.34013 Boehringer Ingelheim Investigational Site
      • Barcelona, Spain
        • 1264.3.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, Spain
        • 1264.3.34008 Boehringer Ingelheim Investigational Site
      • Borges del Camp- Tarragona, Spain
        • 1264.3.34005 Boehringer Ingelheim Investigational Site
      • Canet de Mar - Barcelona, Spain
        • 1264.3.34006 Boehringer Ingelheim Investigational Site
      • Centelles - Barcelona, Spain
        • 1264.3.34010 Boehringer Ingelheim Investigational Site
      • L'Hospitalet de Llobregat, Spain
        • 1264.3.34009 Boehringer Ingelheim Investigational Site
      • L'Hospitalet de Llobregat - Barcelona, Spain
        • 1264.3.34004 Boehringer Ingelheim Investigational Site
      • Sant Adrià del Besós- Barcelona, Spain
        • 1264.3.34002 Boehringer Ingelheim Investigational Site
      • Tarrega - Lleida, Spain
        • 1264.3.34007 Boehringer Ingelheim Investigational Site
      • Valencia, Spain
        • 1264.3.34012 Boehringer Ingelheim Investigational Site
      • Vic - Barcelona, Spain
        • 1264.3.34011 Boehringer Ingelheim Investigational Site
  • United Kingdom
      • Annan, United Kingdom
        • 1264.3.44032 Boehringer Ingelheim Investigational Site
      • Ash Vale, Aldershot, United Kingdom
        • 1264.3.44028 Boehringer Ingelheim Investigational Site
      • Baillieston, Glasgow, United Kingdom
        • 1264.3.44029 Boehringer Ingelheim Investigational Site
      • Balham, United Kingdom
        • 1264.3.44008 Boehringer Ingelheim Investigational Site
      • Bradford on Avon, United Kingdom
        • 1264.3.44021 Boehringer Ingelheim Investigational Site
      • Burbage, United Kingdom
        • 1264.3.44019 Boehringer Ingelheim Investigational Site
      • Chesterfield, United Kingdom
        • 1264.3.44012 Boehringer Ingelheim Investigational Site
      • Chestfield, Whitstable, United Kingdom
        • 1264.3.44027 Boehringer Ingelheim Investigational Site
      • Chippenham, United Kingdom
        • 1264.3.44011 Boehringer Ingelheim Investigational Site
      • Johnstone, United Kingdom
        • 1264.3.44033 Boehringer Ingelheim Investigational Site
      • Midsomer Norton, United Kingdom
        • 1264.3.44007 Boehringer Ingelheim Investigational Site
      • Paisley, United Kingdom
        • 1264.3.44034 Boehringer Ingelheim Investigational Site
      • Warminster, United Kingdom
        • 1264.3.44031 Boehringer Ingelheim Investigational Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States
        • 1264.3.01026 Boehringer Ingelheim Investigational Site
      • Montgomery, Alabama, United States
        • 1264.3.01021 Boehringer Ingelheim Investigational Site
      • Muscle Shoals, Alabama, United States
        • 1264.3.01020 Boehringer Ingelheim Investigational Site
    • Arizona
      • Chandler, Arizona, United States
        • 1264.3.01062 Boehringer Ingelheim Investigational Site
      • Mesa, Arizona, United States
        • 1264.3.01064 Boehringer Ingelheim Investigational Site
    • California
      • Carmichael, California, United States
        • 1264.3.01049 Boehringer Ingelheim Investigational Site
      • Chino, California, United States
        • 1264.3.01078 Boehringer Ingelheim Investigational Site
      • Concord, California, United States
        • 1264.3.01031 Boehringer Ingelheim Investigational Site
      • Lakewood, California, United States
        • 1264.3.01037 Boehringer Ingelheim Investigational Site
      • Los Angeles, California, United States
        • 1264.3.01065 Boehringer Ingelheim Investigational Site
      • Norwalk, California, United States
        • 1264.3.01006 Boehringer Ingelheim Investigational Site
      • Rancho Cucamonga, California, United States
        • 1264.3.01001 Boehringer Ingelheim Investigational Site
      • San Diego, California, United States
        • 1264.3.01059 Boehringer Ingelheim Investigational Site
      • Tarzana, California, United States
        • 1264.3.01023 Boehringer Ingelheim Investigational Site
      • Tustin, California, United States
        • 1264.3.01016 Boehringer Ingelheim Investigational Site
      • Valencia, California, United States
        • 1264.3.01058 Boehringer Ingelheim Investigational Site
      • Westlake Village, California, United States
        • 1264.3.01083 Boehringer Ingelheim Investigational Site
    • Colorado
      • Denver, Colorado, United States
        • 1264.3.01027 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Norwalk, Connecticut, United States
        • 1264.3.01033 Boehringer Ingelheim Investigational Site
    • Florida
      • Boca Raton, Florida, United States
        • 1264.3.01035 Boehringer Ingelheim Investigational Site
      • Clearwater, Florida, United States
        • 1264.3.01015 Boehringer Ingelheim Investigational Site
      • Hialeah, Florida, United States
        • 1264.3.01082 Boehringer Ingelheim Investigational Site
      • Jacksonville, Florida, United States
        • 1264.3.01036 Boehringer Ingelheim Investigational Site
      • Longwood, Florida, United States
        • 1264.3.01013 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1264.3.01038 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1264.3.01042 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1264.3.01079 Boehringer Ingelheim Investigational Site
      • Port Orange, Florida, United States
        • 1264.3.01019 Boehringer Ingelheim Investigational Site
      • St. Cloud, Florida, United States
        • 1264.3.01018 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, United States
        • 1264.3.01009 Boehringer Ingelheim Investigational Site
      • Tampa, Florida, United States
        • 1264.3.01012 Boehringer Ingelheim Investigational Site
    • Georgia
      • Atlanta, Georgia, United States
        • 1264.3.01008 Boehringer Ingelheim Investigational Site
      • Atlanta, Georgia, United States
        • 1264.3.01055 Boehringer Ingelheim Investigational Site
      • Atlanta, Georgia, United States
        • 1264.3.01061 Boehringer Ingelheim Investigational Site
      • Blue Ridge, Georgia, United States
        • 1264.3.01074 Boehringer Ingelheim Investigational Site
      • Cartersville, Georgia, United States
        • 1264.3.01084 Boehringer Ingelheim Investigational Site
      • Perry, Georgia, United States
        • 1264.3.01060 Boehringer Ingelheim Investigational Site
      • Savannah, Georgia, United States
        • 1264.3.01050 Boehringer Ingelheim Investigational Site
    • Illinois
      • Chicago, Illinois, United States
        • 1264.3.01077 Boehringer Ingelheim Investigational Site
    • Indiana
      • Brownsburg, Indiana, United States
        • 1264.3.01052 Boehringer Ingelheim Investigational Site
      • Evansville, Indiana, United States
        • 1264.3.01075 Boehringer Ingelheim Investigational Site
      • Evansville, Indiana, United States
        • 1264.3.01076 Boehringer Ingelheim Investigational Site
      • Franklin, Indiana, United States
        • 1264.3.01073 Boehringer Ingelheim Investigational Site
    • Kansas
      • Wichita, Kansas, United States
        • 1264.3.01002 Boehringer Ingelheim Investigational Site
      • Wichita, Kansas, United States
        • 1264.3.01007 Boehringer Ingelheim Investigational Site
    • Kentucky
      • Lexington, Kentucky, United States
        • 1264.3.01010 Boehringer Ingelheim Investigational Site
    • Louisiana
      • New Orleans, Louisiana, United States
        • 1264.3.01028 Boehringer Ingelheim Investigational Site
      • Sunset, Louisiana, United States
        • 1264.3.01029 Boehringer Ingelheim Investigational Site
    • Maryland
      • Hyattsville, Maryland, United States
        • 1264.3.01069 Boehringer Ingelheim Investigational Site
    • Michigan
      • Southfield, Michigan, United States
        • 1264.3.01066 Boehringer Ingelheim Investigational Site
    • Montana
      • Great Falls, Montana, United States
        • 1264.3.01057 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Burlington, North Carolina, United States
        • 1264.3.01045 Boehringer Ingelheim Investigational Site
      • Charlotte, North Carolina, United States
        • 1264.3.01044 Boehringer Ingelheim Investigational Site
    • Ohio
      • Zanesville, Ohio, United States
        • 1264.3.01022 Boehringer Ingelheim Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • 1264.3.01032 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Fleetwood, Pennsylvania, United States
        • 1264.3.01051 Boehringer Ingelheim Investigational Site
      • Pittsburgh, Pennsylvania, United States
        • 1264.3.01025 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Columbia, South Carolina, United States
        • 1264.3.01081 Boehringer Ingelheim Investigational Site
      • Greer, South Carolina, United States
        • 1264.3.01003 Boehringer Ingelheim Investigational Site
    • Tennessee
      • Kingsport, Tennessee, United States
        • 1264.3.01011 Boehringer Ingelheim Investigational Site
    • Texas
      • Corpus Christi, Texas, United States
        • 1264.3.01017 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, United States
        • 1264.3.01067 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1264.3.01004 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1264.3.01039 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1264.3.01041 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1264.3.01047 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1264.3.01070 Boehringer Ingelheim Investigational Site
      • Killeen, Texas, United States
        • 1264.3.01040 Boehringer Ingelheim Investigational Site
      • Midland, Texas, United States
        • 1264.3.01048 Boehringer Ingelheim Investigational Site
      • New Braunfels, Texas, United States
        • 1264.3.01030 Boehringer Ingelheim Investigational Site
      • North Richland Hills, Texas, United States
        • 1264.3.01071 Boehringer Ingelheim Investigational Site
      • Plano, Texas, United States
        • 1264.3.01085 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, United States
        • 1264.3.01046 Boehringer Ingelheim Investigational Site
    • Virginia
      • Norfolk, Virginia, United States
        • 1264.3.01056 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  1. Diagnosis of type 2 diabetes mellitus prior to informed consent
  2. Male and female patients with insufficient glycaemic control (HbA1c >= 7.0 to <= 10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within 10 weeks prior to start of the run-in period (date of Visit 2)
  3. Age >= 18 and <= 80 years at start date of Visit 1 (Screening)
  4. BMI <= 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)
  5. Signed and dated written informed consent by start date of Visit 1 in accordance with GCP and local legislation

Exclusion criteria:

  1. Uncontrolled hyperglycaemia with a confirmed glucose level > 240 mg/dl (> 13.3 mmol/l) after an overnight fast during screening or placebo run-in period (cf. Section 3.3.4.1)
  2. Myocardial infarction within 6 months, stroke or TIA within 3 months prior to informed consent
  3. Clinical evidence of active liver disease (e.g. jaundice) or the ALT level > 2.5 times the upper limit of normal (according to pioglitazone label)
  4. Bariatric surgery, performed within the past 2 years prior to informed consent or planned at the time of informed consent
  5. Gastrointestinal surgeries prior to informed consent that induce chronic malabsorption
  6. Known hypersensitivity or allergy to the investigational products (linagliptin and/or pioglitazone) or their excipients (including matching placebos)

  7. Contraindications to pioglitazone as defined in the local prescribing information (SPC), particularly :

    • Diagnose of heart failure or history of heart failure
    • Haemodialysis patients, due to limited experience with pioglitazone
  8. Treatment with gemfibrozil, montelukast, trimethoprim, or rifampicin - according to pioglitazone label and respective restrictions in Section 4.2.2
  9. Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, or insulin within 3 months prior to informed consent
  10. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent
  11. Alcohol or drug abuse within the 3 months prior to informed consent or history of alcoholism
  12. Current treatment with systemic corticosteroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent
  13. Participation in another trial with an investigational drug within 30 days prior to informed consent
  14. Any other clinical condition as judged by the investigator that would not allow the safe completion of the protocol, e.g. inability of patients to comply with study procedures

  15. Pre-menopausal women (last menstruation <= 1 year prior to informed consent) who:

    • are nursing or pregnant or
    • are of child-bearing potential (i.e. not permanently sterilised) and are not practicing a highly effective method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.

    A highly effective method of birth control is defined - according to the Note for Guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) - as those which result in a low failure rate (i. e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices/systems (IUDs/IUSs), sexual abstinence or vasectomised partner

  16. Symptomatic gallbladder disease in the last six months
  17. Medical history of pancreatitis.
  18. Patients with urinary bladder cancer or a history of urinary bladder cancer or uninvestigated macroscopic haematuria
  19. Any other contraindication or restriction for use of pioglitazone in accordance with the local prescribing information for pioglitazone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Pioglitazone 15 mg
Pioglitazone Capsules 15 mg once daily
Drug: Pioglitazone 15 mg
Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
Active Comparator: Pioglitazone 30 mg
Pioglitazone Capsules 30 mg once daily
Drug: Pioglitazone 30 mg
Pioglitazone Capsules 30 mg once daily for up to 84 weeks
Active Comparator: Pioglitazone 45 mg
Pioglitazone Capsules 45 mg once daily
Drug: Pioglitazone 45 mg
Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
Active Comparator: Linagliptin 5mg
Linagliptin 5mg Tablets once daily
Drug: Linagliptin 5mg
Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Experimental: Linagliptin 5mg / Pioglitazone 15 mg
Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC
Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Experimental: Linagliptin 5mg / Pioglitazone 30 mg
Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC
Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
Experimental: Linagliptin 5mg / Pioglitazone 45 mg
Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC
Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in HbA1c After 30 Weeks of Treatment.
Time Frame: Baseline and 30 weeks
HbA1c is measured as a percentage. The change from baseline is the Week 30 HbA1c minus the baseline HbA1c.
Baseline and 30 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 7.0% After 30 Weeks of Treatment
Time Frame: Baseline and 30 weeks
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
Baseline and 30 weeks
Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of < 6.5% After 30 Weeks of Treatment
Time Frame: Baseline and 30 weeks
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
Baseline and 30 weeks
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 30 Weeks of Treatment)
Time Frame: Baseline and 30 weeks
Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.
Baseline and 30 weeks
HbA1c Change From Baseline by Visit Over Time
Time Frame: Baseline, week 6, week 12, week 18, week 24, week 30

HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes fixed effects for treatment, continuous baseline HbA1c, prior andi-diabetic medication, country, visit and treatment.

by visit interaction.
Baseline, week 6, week 12, week 18, week 24, week 30
Fasting Plasma Glucose (FPG) Change From Baseline After 30 Weeks of Treatment
Time Frame: Baseline and 30 weeks
The change from baseline is the FPG after 30 weeks minus the baseline FPG.
Baseline and 30 weeks
Fasting Plasma Glucose (FPG) Change From Baseline by Visit Over Time
Time Frame: Baseline, week 6, week 12, week 18, week 24, week 30
The change from baseline is the FPG over time minus the baseline FPG. Model includes fixed effects for treatment, continuous baseline FPG, continuous baseline HbA1c, prior anti-diabetic medication, country, visit and treatment by visit interaction
Baseline, week 6, week 12, week 18, week 24, week 30
Two-hour Postprandial Glucose (2hPPG) Change From Baseline at Week 30 by Meal Tolerance Test (MTT)
Time Frame: Baseline and 30 weeks
The change from baseline is the 2hPPG after 30 weeks minus the baseline 2hPPG.
Baseline and 30 weeks
Time to First Use of Rescue Therapy
Time Frame: 30 weeks
Proportion of patients at 30 weeks with rescue therapy using Kaplan-Meier analysis.
30 weeks
Incidence of Rescue Therapy During the First 30 Weeks of Treatment
Time Frame: 30 weeks
Rescue therapy was defined to include any new antidiabetic medication taken for hyperglycemia and introduced on or after the start date of study treatment and before the end date of study treatment.
30 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Collaborators

Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2010

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

August 16, 2010

First Submitted That Met QC Criteria

August 16, 2010

First Posted (Estimate)

August 17, 2010

Study Record Updates

Last Update Posted (Estimate)

October 20, 2014

Last Update Submitted That Met QC Criteria

October 9, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1264.3
  • 2008-008127-15 (EudraCT Number: EudraCT)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Pioglitazone 15 mg

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe